Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Area of Science:

• Genetics and Molecular Biology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading global cause of mortality, significantly impacting quality of life and productivity.
• Prevalent risk factors including obesity, type 2 diabetes mellitus, hypertension, and hyperlipidemia contribute to the high burden of CVD.
• Current traditional CVD interventions provide symptomatic relief but incur substantial economic costs and may require lifelong prescription.

Purpose of the Study:

• To review the various risk factors contributing to cardiovascular disease.
• To discuss the current perspectives and limitations of traditional cardiovascular medications.
• To focus on the potential of epigenetic therapeutics as alternative or complementary treatments for CVD.

Main Methods:

• This review synthesizes current literature on cardiovascular disease risk factors and traditional treatments.
• It explores the emerging field of epigenetics and its application to cardiovascular medicine.
• The review focuses on understanding how epigenetic modifications can be targeted for therapeutic benefit in CVD.

Main Results:

• Epigenetic interventions modulate gene expression by altering genome organization, not DNA sequence.
• Epigenetic changes are heritable, reversible, and influenced by environmental factors, offering dynamic therapeutic potential.
• Epigenetic approaches present a novel strategy to address the underlying pathophysiology of diverse cardiovascular conditions.

Conclusions:

• Epigenetic therapies offer a new frontier in cardiovascular medicine, potentially overcoming limitations of traditional treatments.
• By targeting the epigenetic level, these novel interventions may provide more comprehensive and sustainable management of CVD.
• Further research into epigenetic therapeutics could lead to improved treatment strategies, offering hope for a better quality of life for CVD patients.